The Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum.

NCT03073902 | Completed

• 1 other identifier: XQonc-006
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The detection of tissue PD-L1 immunohistochemistry in Non-small cell lung cancer (NSCLC) has an important role in guiding for the treatment of immune detection point. At the same time,tissue detection is time-consuming and laborious, liquid biopsy can reflect the information of tumor tissue,PD-L1 expression in serum and peripheral blood T cell are expected to be simple, rapid, non-invasive means of detection. The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum..The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum.By using variance analysis of repeated measures design information. Thus exploring the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum,guiding clinical practice of immunotherapy.

Conditions

NSCLC

Outcome Measures

Primary Outcomes (2)

• The match rate of PD-L1 protein expression in non-small lung cancer tissue and peripheral blood T cell .

  consistency

  up to two years

• The match rate of PD-L1 protein expression in non-small lung cancer tissue and serum.

  consistency

  up to two years

Study Arms (1)

Observed group

The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum.The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum by using variance analysis of repeated measures design information.

Diagnostic Test: Liquid biopsy

Interventions

Liquid biopsy DIAGNOSTIC_TEST

Liquid biopsy

Observed group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Pathological histology and/or cytology confirmed non-small lung cancer

You may qualify if:

• Pathological histology and/or cytology confirmed non-small lung cancer;
• Voluntarily enrolled to participate in,better compliance, cooperate with experimental observations, and sign informed consent.

You may not qualify if:

• Vital organs (e.g., heart, liver, kidney) have serious dysfunction;
• Patients with a history of autoimmune disease;
• Patients with participating in other clinical trials at the same time;
• Other cases that researchers believe that patients should not participate in the present trial.

Sponsors & Collaborators

• Xinqiao Hospital of Chongqing: lead

Study Sites (1)

Xinqiao Hospital of Chongqing

Chongqing, 400000, China

Location

MeSH Terms

Interventions

Liquid Biopsy

Intervention Hierarchy (Ancestors)

Biopsy; Cytodiagnosis; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Specimen Handling; Investigative Techniques

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Deputy Director,Head of Oncology department, Principal Investigator, Clinical Professor

Study Record Dates

• First Submitted: February 26, 2017
• First Posted: March 8, 2017
• Study Start: March 25, 2017
• Primary Completion: March 31, 2018
• Study Completion: December 10, 2018
• Last Updated: December 28, 2018

Record last verified: 2018-12

Locations

CN (1)